Chenopodium formosanum (Taiwanese Red Quinoa), historically referred to as the "ruby of grains," is rich in anthocyanins, polyphenols, and high-quality proteins. However, the functional health product market has long relied on imported raw materials, suffered from a lack of molecular-level scientific validation, and faced standardization bottlenecks during manufacturing.

To solve these pain points, a cross-institutional research team led by Distinguished Professor Cheng Kuang-cheng from the Institute of Food Science and Technology at National Taiwan University (NTU) has established a "precision fermentation" platform featuring four integrated innovative technological strategies. This system successfully bio-transforms Taiwanese Red Quinoa into high-value functional ingredients with potent antioxidant, anti-inflammatory, and anti-aging properties.

Four Strategic Integrations: Connecting Microbiology, Molecular Biology, and AI

1. Scalable Bioreactor Modules: Completed scale-up validation from 3-liter to 30-liter bioreactors, maintaining a batch-to-batch Relative Standard Deviation (RSD) of key functional ingredients below 5%, securing the foundation for standardized mass production.
2. Multi-Omics Mechanistic Elucidation: Integrated transcriptomics and metabolomics via LC-MS/MS untargeted metabolomic analysis to identify 20 significantly differentiated post-fermentation metabolites (including short-chain peptides, glycosides, and fatty acid derivatives), mapping out precise biological mechanisms.
3. The Trinity Purification Platform: Established a coupled purification workflow utilizing Tangential Flow Filtration (TFF), Fast Protein Liquid Chromatography (FPLC), and preparative-scale HPLC to isolate and identify Glycine-rich peptides with targeted physiological activities, achieving a purification reproducibility RSD under 3.2%.
4. AI-Driven Molecular Docking: Introduced computer-aided molecular simulation and predictive modeling to pre-validate efficacy, enhancing R&D logic and clinical credibility.

Critical In Vitro and In Vivo Validation Data

The Chenopodium formosanum fermented ethanolic extract ($200 mutext{g/mL}$) demonstrated a 38% inhibition rate of Reactive Oxygen Species (ROS) in murine lung macrophages induced by PM2.5. Furthermore, mRNA expression levels of inflammatory cytokines $ILtext{-}6$ and $TNFtext{-}alpha$ decreased by 34% and 29% respectively, validating its anti-inflammatory capacity mediated via the $NFtext{-}kappa B$ signaling pathway. Concurrently, the purified Glycine-rich peptides derived from fermented-sprouted quinoa achieved a 32% reduction in SA-$beta$-Gal-positive cells within non-replicative cellular senescence models while upregulating antioxidant gene expression by 38%, demonstrating clear anti-aging potential.

Tech Transfer, Intellectual Property, and Commercialization Pipelines

Professor Cheng emphasized that precision fermentation provides transparency on ingredient composition, efficacy, and reproducibility. The core IP portfolio has secured three granted Taiwan Invention Patents (covering the quinoa heptapeptide, sprouted quinoa extracts, and fermented dairy formulations).

Two technology transfers have been finalized, licensing commercial rights to Fu Heng Technology and Shen Ji Distillery to develop low-GI, antihypertensive, and glucose-metabolism-regulating functional dairy products. A third technology package has completed independent asset valuation and is ready for licensing. The team's research has been published across multiple Q1 international journals, including Food Research International and the Journal of Ethnopharmacology, and Professor Cheng was honored as a 2024 International Academy of Food Science and Technology (IAFoST) Fellow.

The team's commercial business model is structured around B2B raw material supply and out-licensing. The short-term focus targets functional food and cosmetic brands for high-performance ingredient integration; the mid-term outlook involves OEM/ODM semi-finished product partnerships; and the long-term objective integrates clinical trial resources to establish a proprietary functional ingredient seal of certification. This strategy aims to leverage Taiwan's native botanical profiles to enter premium health product markets across Japan, the United States, and Southeast Asia.

Resource:《新創動態》精準發酵解鎖臺灣紅藜潛力　抗老抗炎活性胜肽搶攻全球保健市場